$Acurx Pharmaceuticals, LLC*(ACXP)$Pfizer Clostirdium difficile vaccine failed to meet its primary end point in their phase 3 clinical trial. Good news for ACURX investor with one less competitor.
$Acurx Pharmaceuticals, LLC*(ACXP)$Company has alot of potential. With 100% cure rate at endpoint during phase 2a trial. Next value inflection point will be phase 2b.